'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung)

This is a phase II, non-randomised study examining the safety of treating high risk centrally located non-small cell lung cancer (NSCLC) tumours and single pulmonary oligometastatic lesions using radiation therapy (RT), for patients whose disease is inoperable. The method of delivering the RT in this study is image guided stereotactic ablative radiation therapy (IG-SABR). This method involves using imaging to ensure the radiation is being delivered to the correct location within the body and using higher than normal doses per treatment (fraction) to treat the lung cancer (NSCLC)/oligometastati

Trial Details

NCT ID

NCT04375904

Phase

PHASE2

Sponsor

Cancer Trials Ireland

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR)

Locations (sample)

• Dublin, Ireland|53.33306,-6.24889
• Dublin, Ireland|53.33306,-6.24889

Key Eligibility Criteria

• Written informed consent obtained prior to any study-specific procedures
• ≥ 18 years of age
• Life expectancy \>6 months
• ECOG (Eastern Cooperative Oncology Group) performance status 0-2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →